e-learning
resources
Milan 2017
Sunday, 10.09.2017
COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes
M. Dransfield (Birmingham, United States of America)
Source:
International Congress 2017 – COPD management
Session:
COPD management
Session type:
Thematic Poster
Number:
1069
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Dransfield (Birmingham, United States of America). Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes. 1069
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses
Source: International Congress 2017 – COPD management
Year: 2017
Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study
Source: International Congress 2017 – Management of COPD
Year: 2017
Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Evaluation of adherence of patients with asthma to treatment by single combination inhaler
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 250s
Year: 2002
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018
Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations?
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019
Influence of treatment by single combined inhaler on adherence of patients with asthma
Source: Annual Congress 2009 - Respiratory physiology
Year: 2009
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 252s
Year: 2004
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Symptomatic burden of COPD for patients receiving dual or triple therapy
Source: International Congress 2017 – Management of COPD
Year: 2017
The IMPACT of triple
versus
dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018
TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept